NightstaRx raises $35M series B

Gene therapy company NightstaRx Ltd. (London, U.K.) raised $35 million in a series B round led by New Enterprise Associates. Founding investor Syncona Partners, which is a Wellcome Trust subsidiary, also participated. NEA's David Mott joined NightstaRx's board. ...